Assessment of the Utility of BIOMONITOR to Identify Atrial Fibrillation (AF) in Ablation Candidates Using Precise AF Detection

Atrial Fibrillation Clinical Trial

— BIO-Precision  

Official title:

BIO-Precision Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04076917
• Other study ID #: BIO-Precision
• Status: Terminated
• Start date: September 25, 2019
• Est. completion date: February 24, 2021

Study information

• Verified date: February 2022
• Source: Biotronik, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the diagnostic utility of BIOTRONIK's subcutaneous cardiac rhythm monitor for the detection of AF prior to an ablation procedure.

Description:

BIO-Precision is a post-market study investigating the utility of atrial fibrillation (AF) detection using BIOTRONIK's subcutaneous cardiac rhythm monitor, BIOMONITOR. The purpose of this study is to evaluate the diagnostic utility of BIOTRONIK's BIOMONITOR for the detection and confirmation of AF prior to an ablation procedure. Study population includes patients with paroxysmal AF being evaluated for an AF ablation. Holter monitoring for 48 hours will be performed after insertion of the BIOMONITOR but prior to AF ablation. This study will enroll up to 100 subjects, to obtain 60 usable Holter recordings, at 5 study sites within the United States (U.S.). Study subjects will be followed for three months after the completion of a 48 hr Holter monitor.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 84
• Est. completion date: February 24, 2021
• Est. primary completion date: February 24, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meet the indications for subcutaneous cardiac rhythm monitor insertion according to local regulations

• Patient is able to understand the nature of the study and provide written informed consent

• Inserted within the prior 30 days, or scheduled for insertion within 14 days, with BIOTRONIK's most current subcutaneous cardiac rhythm monitor

• Diagnosed with paroxysmal atrial fibrillation and being evaluated for an AF ablation

• Agree to wearing a 48 hr Holter monitor

• Able and willing to complete all study visits at the study site for the study duration

• Able and willing to use a CardioMessenger® and accepts Home Monitoring concept

• Age greater than or equal to 18 years

Exclusion Criteria:

• Patient meets none of the indications for a BIOMONITOR

• Patient is planned to have an ablation prior to BIOMONITOR insertion or 48 hr Holter monitoring visit

• Patient is currently diagnosed with long-standing persistent or permanent AF

• Patient is enrolled in another study that may change or alter the cardiac rhythm that occurs prior to the completion of the Holter

• Currently indicated for or implanted with a pacemaker, ICD device, or hemodynamic monitoring system

• Life expectancy less than 6 months

• Patients reporting pregnancy at the time of enrollment

For patients enrolled after BIOMONITOR insertion:

• R-wave sensing <0.25 mV according to the most recent remote or in-person device interrogation available prior to enrollment

After the pre-Holter observation period but prior to 48 hr Holter monitoring initiation, confirm the absence of the following exclusion criteria based on the remote interrogation collected at the end of the observation period:

• No AF episodes observed or transmitted during pre-Holter observation period

• R-wave sensing <0.25 mV during pre-Holter observation period as reported by the 24 hr mean or mean value since last follow-up

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
United States	The Ohio State University	Columbus	Ohio
United States	Cardiovascular Associates, Inc.	Kissimmee	Florida
United States	St. Louis Heart and Vascular	Saint Louis	Missouri
United States	ProMedica Physicians Cardiology	Toledo	Ohio
United States	Florida Cardiology	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Biotronik, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic Sensitivity	The diagnostic sensitivity of the BIOMONITOR will be determined by comparing AF events detected by the BIOMONITOR and 48 hr Holter monitor for each subject. Diagnostic sensitivity is the ability of the BIOMONITOR to correctly identify subjects who have true AF as determined by the Holter monitor. It is calculated as the number of participants with a true BIOMONITOR AF detection divided by the sum of the number of participants with a true BIOMONITOR AF detection and the number of participants with a false negative BIOMONITOR AF detection.	48 hours